Skip to main content
logo
Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.7224
+0.0064 (0.89%)
At close: Aug 24, 2026, 4:00 PM EDT
0.7085
-0.0139 (-1.92%)
After-hours: Aug 24, 2026, 5:07 PM EDT

Jasper Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
17.9620.2820.4217.0816.5711.41
Research & Development
34.961.355.8251.7934.6325.42
Operating Expenses
52.8681.5876.2468.8651.236.83
Operating Income
-52.86-81.58-76.24-68.86-51.2-36.83
Interest & Investment Income
0.931.745.065.20.7-
Other Non Operating Income (Expenses)
22.476.34-0.09-0.827.09-3.08
EBT Excluding Unusual Items
-29.47-73.5-71.27-64.48-43.41-39.91
Merger & Restructuring Charges
-2.3-2.3----
Other Unusual Items
---0.025.739.28
Pretax Income
-31.77-75.8-71.27-64.47-37.69-30.64
Net Income
-31.77-75.8-71.27-64.47-37.69-30.64
Net Income to Common
-31.77-75.8-71.27-64.47-37.69-30.64
Net Income Growth
------
Shares Outstanding (Basic)
2619151041
Shares Outstanding (Diluted)
2619151041
Shares Change
71.73%31.42%39.72%186.15%220.19%558.67%
EPS (Basic)
-1.23-3.95-4.89-6.18-10.33-26.89
EPS (Diluted)
-1.23-3.95-4.89-6.18-10.33-26.89
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-60.33-77.17-63.15-52.33-46.43-36.11
Free Cash Flow Per Share
-2.33-4.03-4.33-5.01-12.73-31.69
EBITDA
-52.3-80.53-74.87-67.75-50.22-36.46
D&A For EBITDA
0.561.061.371.110.980.38
EBIT
-52.86-81.58-76.24-68.86-51.2-36.83
SEC Filings: 10-K · 10-Q